COCP
OPK
FLNT
BCDA

Phillip Frost, MD, et al.

Known title: CEO & ChairmanCIK: 0000898860

Phillip Frost, MD, et al.'s purchase track record

How the stock did after each of Phillip Frost, MD, et al.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
50
of 51 since September 14, 2021
Stock higher 6 months later
32%
3 months: 40%
Median 6-month return
-14.1%
3 months: -4.8%
Beat the S&P 500
28%
median -18.0% vs. index
PurchaseStockAmount3 months6 months
8/3/2026COCP$80Kpendingpending
2/24/2026COCP$20K+13.0%+13.0%
2/6/2026COCP$47K+48.4%+9.3%
12/24/2025COCP$130K+11.3%+8.3%
11/25/2025COCP$23K+6.4%+20.2%
11/18/2025OPK$2.98M-4.7%-10.2%
10/31/2025OPK$213K-7.3%-19.1%
8/8/2025OPK$891K+7.2%-0.8%
4/8/2025OPK$354K-6.9%+5.5%
3/28/2025OPK$419K-22.4%-14.7%
3/17/2025OPK$348K-26.5%-23.8%
2/28/2025OPK$115K-21.8%-20.7%
1/28/2025OPK$70K-6.7%-10.0%
1/15/2025OPK$961K-3.4%-7.5%
12/11/2024OPK$980K+11.9%-15.1%
11/22/2024OPK$464K+6.3%-20.3%
11/8/2024OPK$584K+5.9%-18.4%
5/17/2024OPK$338K+17.4%+24.2%
3/12/2024OPK$1.90M+41.9%+71.0%
2/21/2024OPK$1.49M+30.7%+60.4%
2/7/2024OPK$1.46M+25.0%+28.0%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

this person other insiders at COCP

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

OPKO Health Shares Rise on $722M BioReference Asset Sale. OPKO Health announced it sold BioReference laboratory assets to Labcorp for $722 million, a key part of Labcorp’s up to $872 million acquisition. The transaction was reflected in a sharp increase in OPKO’s stock price. The deal highlights OPKO’s focus on divesting non‑core assets. The move follows Labcorp’s broader strategy to expand its laboratory services.

this person other insiders at OPK
this person other insiders at FLNT

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 2, 2026

BioCardia Resubmits Helix Catheter Pre-Submission to FDA. BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.

this person other insiders at BCDA

Transaction History

COCP▲ Buy$10K
COCP▲ Buy$71K
COCP▲ Buy$20K
COCP▲ Buy$47K
COCP▲ Buy$47K
COCP▲ Buy$19K
COCP▲ Buy$39K
COCP▲ Buy$24K
COCP▲ Buy$2K
COCP▲ Buy$2K
COCP▲ Buy$19K
OPK▲ Buy$118K
OPK▲ Buy$255K
OPK▲ Buy$5K
OPK▲ Buy$133K
OPK▲ Buy$257K
OPK▲ Buy$157K
OPK▲ Buy$2K
OPK▲ Buy$216K
OPK▲ Buy$18K
OPK▲ Buy$62K
OPK▲ Buy$282K
OPK▲ Buy$33K
OPK▲ Buy$87K
OPK▲ Buy$39K
OPK▲ Buy$17K
OPK▲ Buy$28K
OPK▲ Buy$387
OPK▲ Buy$75K
OPK▲ Buy$262K
OPK▲ Buy$205K
OPK▲ Buy$46K
OPK▲ Buy$43K
OPK▲ Buy$510
OPK▲ Buy$89K
OPK▲ Buy$19K
OPK▲ Buy$107K
OPK▲ Buy$550
OPK▲ Buy$2K
OPK▲ Buy$271K
OPK▲ Buy$59K
OPK▲ Buy$1
OPK▲ Buy$84K
OPK▲ Buy$62K
OPK▲ Buy$213K
COCP▲ Buy$500K
FLNT▼ Sell$286
OPK▼ Sell$0
OPK▲ Buy$891K
FLNT▼ Sell$455
FLNT▼ Sell$452
OPK▲ Buy$170K
OPK▲ Buy$185K
OPK▲ Buy$165K
OPK▲ Buy$254K
FLNT▲ Buy$230
FLNT▼ Sell$228
OPK▲ Buy$348K
OPK▲ Buy$115K
OPK▲ Buy$70K
OPK▲ Buy$220K
OPK▲ Buy$741K
OPK▲ Buy$199K
OPK▲ Buy$781K
FLNT▼ Sell$324
OPK▲ Buy$305K
OPK▲ Buy$159K
OPK▲ Buy$162K
OPK▲ Buy$422K
COCP▲ Buy—
OPK▲ Buy$0
FLNT▼ Sell$296
OPK▲ Buy$974
OPK▲ Buy$126K
OPK▲ Buy$211K
OPK▲ Buy$437K
OPK▲ Buy$444K
OPK▲ Buy$464K
OPK▲ Buy$559K
OPK▲ Buy$496K
OPK▲ Buy$992K
OPK▲ Buy$1.5M
OPK▲ Buy$489K
BCDA▼ Sell$56K
OPK▲ Buy$386K
OPK▲ Buy$954K
OPK▲ Buy$480K
OPK▲ Buy$1.3M
OPK▲ Buy$6K
OPK▲ Buy$49K
OPK▲ Buy$31K
OPK▲ Buy$626
OPK▲ Buy$175K
OPK▲ Buy$62K
OPK▲ Buy$505
OPK▲ Buy$24K
OPK▲ Buy$7K
OPK▲ Buy$62K
OPK▲ Buy$108K
OPK▲ Buy$2K
OPK▲ Buy$100K
OPK▲ Buy$13K
OPK▲ Buy$81K
OPK▲ Buy$87K
OPK▲ Buy$119K
OPK▲ Buy$16K
OPK▲ Buy$192K
OPK▲ Buy$786
OPK▲ Buy$71K
OPK▲ Buy$63K
FLNT▲ Buy$46K
OPK▲ Buy$3K
OPK▲ Buy$3K
OPK▲ Buy$82K
OPK▲ Buy$26K
OPK▲ Buy$11K
OPK▲ Buy$41K
OPK▲ Buy$3K
OPK▲ Buy$7K
OPK▲ Buy$100K
OPK▲ Buy$7K
OPK▲ Buy$17K
OPK▲ Buy$7K
OPK▲ Buy$51K
OPK▲ Buy$47K
OPK▲ Buy$38K
OPK▲ Buy$12K
OPK▲ Buy$10K
OPK▲ Buy$25K
OPK▲ Buy$84K
OPK▲ Buy$17K
OPK▲ Buy$184
OPK▲ Buy$296K
OPK▲ Buy$62K
OPK▲ Buy$916
OPK▲ Buy$325K
OPK▲ Buy$8K
OPK▲ Buy$99K
OPK▲ Buy$6K
OPK▲ Buy$80K
OPK▲ Buy$182
OPK▲ Buy$129K
OPK▲ Buy$48K
OPK▲ Buy$40K
COCP▲ Buy$2.0M
OPK▲ Buy$33K
OPK▲ Buy$75K
OPK▲ Buy$917
OPK▲ Buy$468
OPK▲ Buy$155K
OPK▲ Buy$44K
OPK▲ Buy$336
OPK▲ Buy$44K
OPK▲ Buy$8K
OPK▲ Buy$115K
OPK▲ Buy$3K
OPK▲ Buy$113K
OPK▲ Buy$68K
OPK▲ Buy$14K
OPK▲ Buy$1K
OPK▲ Buy$19K
OPK▲ Buy$10K
OPK▲ Buy$24K
OPK▲ Buy$1K
OPK▲ Buy$94K
OPK▲ Buy$14K
OPK▲ Buy$2K
OPK▲ Buy$16K
OPK▲ Buy$397K
OPK▲ Buy$9K
OPK▲ Buy$122K
OPK▲ Buy$6K
OPK▲ Buy$25K
OPK▲ Buy$26K
BCDA▲ Buy$1000K
OPK▲ Buy$51K
OPK▲ Buy$139K
OPK▲ Buy$2K
OPK▲ Buy$86K
OPK▲ Buy$30K
OPK▲ Buy$10K
OPK▲ Buy$113K
OPK▲ Buy$17K
OPK▲ Buy$3K
OPK▲ Buy$7K
OPK▲ Buy$38K
OPK▲ Buy$19K
OPK▲ Buy$72K
OPK▲ Buy$36K
OPK▲ Buy$19K
OPK▲ Buy$10K
OPK▲ Buy$55K
OPK▲ Buy$14K
OPK▲ Buy$4K
OPK▲ Buy$33K
OPK▲ Buy$6K
OPK▲ Buy$4K
OPK▲ Buy$344
OPK▲ Buy$55K
OPK▲ Buy$1K

We use analytics to understand how market-wall is used. No personal data is sold.